Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT04250350 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

206

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

BIOLOGICAL: Lebrikizumab

Sponsor

Eli Lilly and Company

Collaborators

[object Object]